RAP80 Antibody
| Code | Size | Price |
|---|
| PSI-4325-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-4325-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
RAP80 Antibody: RAP80, X2HRIP110, RAP80, RXRIP110, BRCA1-A complex subunit RAP80, Receptor-associated protein 80
Application Note:
RAP80 antibody can be used for detection of RAP80 by Western blot at 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
RAP80 Antibody: RAP80 was initially identified as zinc-finger containing nuclear protein that is highly expressed in testis and interacts with the retinoid-related testis-associated receptor (RTR). Later experiments revealed that RAP80 is recruited by the Coiled-coil domain 98 (CCDC98) protein to the breast cancer-1 protein BRCA1, allowing the formation of BRCA1 foci in response to DNA damage caused by ionizing radiation. Both RAP80 and CCDC98 are required for DNA damage resistance, G2-M checkpoint control, and DNA repair. Cells depleted of either RAP80 or CCDC98 exhibited increased sensitivity to ionizing radiation, although not as much as in BRCA1-depleted cells, suggesting that RAP80 and CCDC98 control only part of the DNA damage response role of BRCA1. At least four isoforms of RAP80 are known to exist.
Background References:
- Yan Z, Kim YS, and Jetten AM. RAP80, a novel nuclear protein that interacts with the retinoid-related testis-associated receptor. J. Biol. Chem.2002; 277:32379-88.
- Wang B, Matsuoka S, Balliff BA, et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science2007; 316:1194-1198.
- Kim H, Huang J, and Chen J. CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage response. Nat. Struct. Mol. Biol.2007; 14:710-5.
- Liu Z, Wu J, and Yu X. CCDC98 targets BRCA1 to DNA damage sites. Nat. Struct. Mol. Biol.2007; 14:716-20.
Buffer:
RAP80 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Pig: (81%)
Immunogen:
RAP80 antibody was raised against a 17 amino acid synthetic peptide from near the carboxy terminus of human RAP80.
The immunogen is located within amino acids 520 - 570 of RAP80.
The immunogen is located within amino acids 520 - 570 of RAP80.
NCBI Gene ID #:
51720
NCBI Official Name:
ubiquitin interaction motif containing 1
NCBI Official Symbol:
UIMC1
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
EAW85043
Protein GI Number:
119605449
Purification:
RAP80 Antibody is affinity chromatography purified via peptide column.
Research Area:
Homeostasis
Swissprot #:
Q96RL1
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | RAP80 Peptide | PSI-4325P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|